Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

AEZS $11.43 3.7500 +48.83%
KBIO $26.63 8.2300 +44.73%
OHRP $4.77 0.8000 +20.15%
CTIX $1.79 0.2190 +13.95%
DRNA $12.26 0.9800 +8.69%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

NWBO $4.70 -0.2700 -5.43%
CYTK $11.71 -0.4000 -3.30%
VBLT $5.69 -0.1900 -3.23%
SRNE $8.41 -0.1700 -1.98%
XBIT $8.59 -0.1600 -1.83%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | Next > | Last >>

ObamaCare Leaves 250 Cancer Patients in Peril

(New York Post) Nov 6, 2015 - Some 250 patients receiving treatment at Memorial Sloan Kettering Cancer Center are facing a crisis because they signed up with the only ObamaCare insurer in New York that provides coverage at the world-renowned hospital — and the insurer is going bust.
read article 

Aetna, OHC Form Oncology Medical Home in Cincinnati and Northern Kentucky

(MarketWatch) Nov 5, 2015 - Cancer patients in greater Cincinnati and northern Kentucky will have access to improved care following the announcement today by OHC and Aetna to create an oncology medical home.
read article 

Statement from ASH President David A. Williams, MD, on Need for Changes to Maintenance of Certification, Comments on Assessment 2020 Report

(ASH) Nov 5, 2015 - For more than 14 years, ASH has actively challenged the ABIM’s Maintenance of Certification (MOC) program on a number of fronts, including the lack of evidence that the program’s requirements improve the quality of medical care.
read press release 

Dr. Reddy’s Shares Fall 14% After FDA Warning

(NASDAQ/Dow Jones Business News) Nov 6, 2015 - The FDA issued warnings about manufacturing at the company’s Miryalaguda factory in Telangana state, which makes active pharmaceutical ingredients, as well as a plant in Duvvada in the state of Andhra Pradesh, which makes oncology drugs, Dr. Reddy’s said.
read article  

FDA Grants Guided Therapeutics’ Request for New Meeting Date to Plan Path Forward for LuViva® Advanced Cervical Scan PMA Application

(Yahoo! Finance) Nov 5, 2015 - November 30 meeting clears scheduling conflict with doctors.
read article 

FDA Clears BriaCell for BriaVax Trial

(BioTuesdays) Nov 4, 2015 - The FDA has given final clearance for BriaCell Therapeutics’ IND to initiate a Phase 1/2a clinical trial of its BriaVax vaccine.
read article 

CytomX and MD Anderson Cancer Center Enter Into Strategic Collaboration for Probody-Enabled CAR-NK Cell Therapies

(MD Anderson) Nov 5, 2015 - Collaboration combines leading research in chimeric antigen receptor (CAR) natural killer (NK) cell therapies with CytomX’s Probody Platform.
read press release 

Juno, Kite, Novartis Yelp 'Oh Merde!' at Cellectis Off-the-Shelf CAR-T Data

(TheStreet) Nov 5, 2015 - On Thursday, investors got the first peek at patient data from an off-the-shelf CAR-T from French drug company Cellectis.
read article 

Bluebird Gene Therapy Narrative Shift: 'Cure' May Elude Some Patients

(TheStreet) Nov 5, 2015 - Bluebird Bio is learning differences in the genetic mutation behind beta-thalassemia, a serious, inherited blood disease, is playing a role in how well patients respond to its experimental gene therapy.
read article 

Never Too Young Coalition-AACR Launch New Fellowships for Young-Onset Colorectal Cancer Research

(AACR) Nov 6, 2015 - The American Association for Cancer Research (AACR) and the Never Too Young Coalition are pleased to offer fellowship opportunities for young-onset colorectal cancer research.
read press release 

Transatlantic Dream Team of Top Researchers Selected To Tackle One of Cancer's Deadliest Forms: Pancreatic Cancer

(AACR) Nov 6, 2015 - Stand Up To Cancer, Cancer Research UK, and The Lustgarten Foundation fund team with $12 million.
read press release 

OXiGENE Announces Positive Initial Data From Phase 1b Study of CA4P in Combination With Pazopanib in Patients With Advanced Recurrent Ovarian Cancer

(CNNMoney) Nov 5, 2015 - OXiGENE, Inc. today announced initial data from a Phase 1b/2 study of the company's lead investigational drug, CA4P, in combination with the anti-angiogenic agent Votrient™ (pazopanib) in patients with advanced recurrent ovarian cancer.
read article 

Inovio's INO-3112 Shows Robust Immune Responses in Patients With Head & Neck Cancer

(TheStreet) Nov 5, 2015 - Inovio Pharmaceuticals, Inc. announced today an interim data analysis showing that its INO-3112 DNA-based immunotherapy generated specific T-cell responses and was well tolerated in all evaluable patients with head and neck cancer associated with human papillomavirus (HPV) types 16 and 18.
read article 

Heat Biologics Reports HS-410 Phase 1 Bladder Cancer Trial Results at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

(StreetInsider) Nov 6, 2015 - Heat Biologics, Inc. announced results from its Phase 1 trial to evaluate safety and immune response to HS-410 (vesigenurtacel-L), after standard of care Bacillus Calmette-Guérin (BCG), for the treatment of high-risk, non-muscle invasive bladder cancer (NMIBC).
read article 

Viralytics and Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. to Collaborate on Combination Clinical Trial of CAVATAK™ and KEYTRUDA® in Lung and Bladder Cancer

(MarketWatch) Nov 6, 2015 - Viralytics Limited announced today that it has entered into a clinical trial collaboration agreement through subsidiaries of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. (known as MSD outside the United States and Canada) to evaluate the combination of Viralytics' investigational cancer immunotherapy CAVATAK™, with MSD's KEYTRUDA®, an anti-PD-1 (programmed death receptor-1) therapy.
read article 

Seattle Genetics Announces More Than 20 Presentations at ASH 2015 Highlighting Progress with Broad ADCETRIS® (Brentuximab Vedotin) Development Plan and Multiple Antibody-Drug Conjugate (ADC) Pipeline Programs

(Yahoo! Finance) Nov 6, 2015 - Seattle Genetics, Inc. today announced that a record number of abstracts were accepted for presentation at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, Florida, December 5-8, 2015.
read article 

Takeda to Present Data from Ixazomib's Phase 3 Study in Relapsed/Refractory Multiple Myeloma at Upcoming American Society of Hematology Annual Meeting

(Takeda) Nov 5, 2015 - Takeda Pharmaceutical Company Limited today announced that it will present Phase 3 data from the TOURMALINE-MM1 ixazomib clinical trial at the 57th American Society of Hematology (ASH) Annual Meeting to be held in Orlando, Florida from December 5 to 8, 2015.
read corporate press release 

Pediatric Low-grade Gliomas With CRAF Fusions May Require Differential and Combinatorial Targeted Therapies

(AACR) Nov 6, 2015 - Unlike pediatric low-grade gliomas (PLGG) that are driven by BRAF fusion proteins, PLGGs that are driven by other forms of RAF fusion proteins, called CRAF fusion proteins, may not respond to single-agent therapy with FDA-approved and investigational RAF inhibitors, suggesting the importance of molecularly stratifying PLGG patients in order to identify appropriate therapies.
read press release 

Loss of SMAD4 Gene in Certain Colorectal Cancers is Associated With Poor Prognosis

(AACR) Nov 6, 2015 - Among colorectal cancers, loss of the gene SMAD4 was significantly more common in cancers arising in the hindgut (the left side of the colon to the rectum) than in cancers arising in the midgut (the right side of the colon) and patients with hindgut-derived tumors with SMAD4 loss had worse recurrence-free survival compared with those with hindgut-derived tumors that retained SMAD4.
read press release 

The Lancet: Adding Ultrasound to Breast Screening Results in Higher Rate of Detection for Women in Japan

(Science Codex) Nov 5, 2015 - Adding ultrasound to standard mammography tests in breast screening could result in improved rates of detection for breast cancer in women in Japan, according to a new study, published in The Lancet.
read article 

TCGA Findings on Papillary Renal Cell Carcinoma and Prostate Cancer

(NCI News Note) Nov 5, 2015 - Two findings from The Cancer Genome Atlas (TCGA) Research Network were recently published on papillary renal cell carcinoma and prostate cancer.
read press release 

First Precision Medicine Trial in Cancer Prevention Identifies Molecular-Based Chemoprevention Strategy

(MD Anderson) Nov 5, 2015 - A team of scientists, led by researchers at The University of Texas MD Anderson Cancer Center and University of California, San Diego Moores Cancer Center, report that a genetic biomarker called loss of heterozygosity or LOH is able to predict which patients with premalignant mouth lesions are at highest risk of developing oral cancer.
read press release 

Why The FDA Rejected A Drug That Cures Lung Cancer -- And What We Can Do To Fix It

(Forbes) Nov 6, 2015 - Ed Silverman, writing in the Boston Globe October 19th, pointed to lung cancer drug Iressa as a "cautionary tale" against using "surrogate endpoints" – signs that point to, but don't guarantee, a given clinical outcome – for FDA drug approvals.
read article 

The Hottest New Cancer Drugs Depend on Gut Microbes

(The Atlantic) Nov 5, 2015 - Immunotherapy doesn’t work for everyone, and a series of new studies might explain why.
read article 

Gene Editing Credited With Eliminating an Infant's Aggressive Cancer in London

(Wall Street Journal) Nov 5, 2015 - A novel gene-editing technique has been used to eliminate an infant's aggressive cancer, a small but significant step in the quest to treat deadly diseases by altering the human genome.
read article (paid subscription required)